Efficacy and Toxicity Profile of Elotuzumab for Multiple Myeloma: A Systematic Review and Meta-Analysis

Conclusion:Results produced in our study suggest that elotuzumab is highly effective when used in pts with RRMM and NDMM. Combination regimens for elo produces an ORR ranging from 79-83% with elo + lena+ dexa, proving that the best results were produced by three drug regimens. Large prospective studies are required to evaluate efficacy and safety of elotuzumab in combination therapies.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Jamil, F., Shafqat, M., Samuel, S., Shah, Z., Durer, C., Durer, S., Sadiq, M., Tariq, M. J., Jose, J. A., Faridi, W., Bakr, M. M., Zahid, U., McBride, A., Safdar, A., Anwer, F. Tags: 653. Myeloma: Therapy, excluding Transplantation Source Type: research